Pfizer-Pharmawert total unterbewertet! 50% möglich! (Seite 212)
eröffnet am 15.05.06 13:00:41 von
neuester Beitrag 25.04.24 21:28:52 von
neuester Beitrag 25.04.24 21:28:52 von
Beiträge: 2.464
ID: 1.060.098
ID: 1.060.098
Aufrufe heute: 4
Gesamt: 330.185
Gesamt: 330.185
Aktive User: 0
ISIN: US7170811035 · WKN: 852009 · Symbol: PFE
25,40
USD
+0,55 %
+0,14 USD
Letzter Kurs 02:04:00 NYSE
Neuigkeiten
25.04.24 · wallstreetONLINE Redaktion |
26.04.24 · Business Wire (engl.)  |
24.04.24 · Business Wire (engl.) |
24.04.24 · Aktienwelt360 |
Ihre wichtigsten Termine: Frische Q1-Zahlen von: Alphabet, Snap, Intel, AstraZeneca, Hermes und NestleWerte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,9000 | +305,04 | |
| 1,3254 | +82,86 | |
| 0,6500 | +25,75 | |
| 6,0000 | +25,00 | |
| 56,69 | +20,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,1200 | -12,17 | |
| 8,5000 | -15,00 | |
| 0,7300 | -18,59 | |
| 92,06 | -19,84 | |
| 2,7280 | -29,14 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 32.499.149 von Rambus2007 am 20.11.07 18:56:09yep, so isse, die selbsternannten Experten von EURamS sind mit die größten Pfeifen aller Börsenprintmedien.
Wer generell auf die Empfehlungen hört und womöglich auch danach handelt, ist selbst schiuld. Meist ist das Gegenteil besser, also kaufen.
Gruss space
Wer generell auf die Empfehlungen hört und womöglich auch danach handelt, ist selbst schiuld. Meist ist das Gegenteil besser, also kaufen.
Gruss space
Antwort auf Beitrag Nr.: 32.497.358 von Red_Eileen am 20.11.07 17:05:33Ohne den "Experten" von Euro am Sonntag ihre charttechnischen Fähigkeiten abzusprechen:
Bei Pfizer geht es immer noch um den weltgroessten Pharmahersteller der für einen Langfristanleger jetzt ein sehr lukratives Investment verspricht und dazu noch eine 5% Div.rendite.
Nichts für den Daytrader oder Zocker, aber über einen längeren Zeitraum sicher besser als jede Empfehlung der Euro.
Bei Pfizer geht es immer noch um den weltgroessten Pharmahersteller der für einen Langfristanleger jetzt ein sehr lukratives Investment verspricht und dazu noch eine 5% Div.rendite.
Nichts für den Daytrader oder Zocker, aber über einen längeren Zeitraum sicher besser als jede Empfehlung der Euro.
München (aktiencheck.de AG) - Die Experten von "EURO am Sonntag" empfehlen die Aktie von Pfizer (ISIN US7170811035/ WKN 852009) zu verkaufen. Pfizer mache Sorgen. Der Hoffnungsträger Exubera, ein Inhalationsmittel für Diabetiker, sei bei den Patienten durchgefallen. Dies koste die Gesellschaft nicht nur 2,8 Milliarden Dollar im dritten Quartal, sondern auch 135 Millionen Dollar Entschädigung für den Partner Nektar Therapeutics. Nektar erhalte ebenfalls die Rechte an dem Produkt. Der Patentablauf für den Cholesterinsenker Lipitor, einem 13-Milliarden-Dollar-Medikament, drohe im Jahr 2010. Zwar sei der Titel billig, jedoch hinsichtlich der Charttechnik angeschlagen. Die Experten von "EURO am Sonntag" raten die Pfizer-Aktie zu verkaufen. (Ausgabe 46) (19.11.2007/ac/a/a)
das könnte heute vielleicht ein bisschen gut tun...
Pfizer legal win might block some Celebrex lawsuits: report
Tue Nov 20, 2007 1:51am EST
NEW YORK (Reuters) - Pfizer Inc scored a victory Monday through a federal ruling that might wipe out some lawsuits alleging its painkiller Celebrex caused heart attacks and strokes, the Wall Street Journal reported in its online edition.
Judge Charles Breyer of the U.S. District Court for the Northern District of California ruled that the plaintiffs in the litigation had not presented scientifically reliable evidence that Celebrex caused heart attacks or strokes when taken at a daily dosage of 200 milligrams, which is the most common dosage, the Journal said.
There are more than 3,000 Celebrex plaintiffs -- according to the ruling -- but it is not clear how many the ruling will affect, the Journal said.
Representatives of Pfizer could not immediately be reached for comment.
"We are pleased with the decision of the federal court, which recognizes the lack of any credible evidence linking Celebrex, at its most common dosage form, with heart attacks or strokes," Pfizer General Counsel Allen Waxman said, according to the Journal.
Pfizer legal win might block some Celebrex lawsuits: report
Tue Nov 20, 2007 1:51am EST
NEW YORK (Reuters) - Pfizer Inc scored a victory Monday through a federal ruling that might wipe out some lawsuits alleging its painkiller Celebrex caused heart attacks and strokes, the Wall Street Journal reported in its online edition.
Judge Charles Breyer of the U.S. District Court for the Northern District of California ruled that the plaintiffs in the litigation had not presented scientifically reliable evidence that Celebrex caused heart attacks or strokes when taken at a daily dosage of 200 milligrams, which is the most common dosage, the Journal said.
There are more than 3,000 Celebrex plaintiffs -- according to the ruling -- but it is not clear how many the ruling will affect, the Journal said.
Representatives of Pfizer could not immediately be reached for comment.
"We are pleased with the decision of the federal court, which recognizes the lack of any credible evidence linking Celebrex, at its most common dosage form, with heart attacks or strokes," Pfizer General Counsel Allen Waxman said, according to the Journal.
Antwort auf Beitrag Nr.: 32.452.584 von lucky27 am 16.11.07 14:33:08Ich würde Pfizer nicht als krankes Unternehmen bezeichnen. Nur für die Zukunft ab 2010 müssen halt jetzt die Weichen gestellt werden.
Vielleicht erfahren wir am 30.11.2007 schon mehr.
Die erste Übernahme wurde gestern bekanntgeben:
Pfizer to Acquire Coley Pharmaceutical Group
Acquisition Will Expand Pfizer’s Investment in Vaccines, Broaden Scope of Research in a Number of Key Therapeutic Areas
NEW YORK & WELLESLEY, Mass.--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today it has entered into an agreement to acquire Coley Pharmaceutical Group, Inc. (NASDAQ: COLY), a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, allergy and asthma disorders, and autoimmune diseases.
Under the terms of the agreement, Pfizer will make a cash tender offer for all of the outstanding common stock of Coley for $8.00 per share, representing an enterprise value of $164 million. The transaction is subject to customary closing conditions, including approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the acquisition by Pfizer of a majority of Coley's shares. Shareholders holding approximately 27% of the Coley shares have entered into agreements to tender their shares in the offer.
“This acquisition is an important component of Pfizer’s vaccine strategy and reflects our commitment to research new and more effective vaccines to prevent infectious diseases and to treat cancers and other debilitating conditions. Coley’s innovative product candidate portfolio and technology have the potential to significantly enhance future vaccine and immunotherapeutic approaches to a broad range of diseases including Alzheimer’s, asthma, infectious disease and oncology, where we already have strong collaborative research in place,” said Jeffrey B. Kindler, chairman and chief executive officer, Pfizer Inc.
Coley is a pioneer in a new class of drug candidates called TLR Therapeutics which work by stimulating or blocking important immune system receptors, called Toll-like receptors (TLRs), which, in turn, direct the immune system to fight disease. Coley has discovered proprietary clinical stage drug candidates targeting TLRs 7, 8 and 9.
“As a pioneer in the field of TLR-based vaccine adjuvants and immunomodulators, Coley is delighted to enter into this agreement with Pfizer, a partner who has demonstrated that they share our vision,” stated Robert L. Bratzler, President and Chief Executive Officer, Coley Pharmaceutical Group. “We believe this transaction is a strong testament to the therapeutic potential of targeting TLR pathways and reflects Pfizer’s commitment to discovering and advancing TLR Therapeutic candidates that may be capable of directing the immune system to treat a wide range of diseases.”
The acquisition is expected to close early in 2008. Lazard Frères and Co, LLC, and Covington & Burling, LLP advised Pfizer on this transaction. JPMorgan and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. advised Coley Pharmaceutical Group.
More information on both companies and the Coley TLR Therapeutics technology can be found at www.pfizer.com and www.coleypharma.com
Conference Call: Coley management will be hosting a conference call and webcast to discuss the transaction today, Friday, November 16, 2007, at 10:00am Eastern Time.
To access the live audio broadcast or the subsequent archived recording of the call, please visit the Investor Center section of the Coley website at www.coleypharma.com. Please log onto Coley’s website several minutes prior to the start of the call to ensure adequate time for any software download that may be required. A replay of this webcast will be available through November 30, 2007.
Investors may participate in the conference call by dialing either +1- 866-314-5232 in the U.S. or +1-617-213-8052 outside the U.S. and typing in the passcode 97926444. A replay of this call will be available at +1-888-286-8010 (U.S.) or +1-617-801-6888 (international) using the passcode 91373615 until November 30, 2007.
The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at www.fulldisclosure.com and institutional investors can access the call via www.streetevents.com.
PFIZER DISCLOSURE NOTICE: The information contained in this release is as of November 16, 2007. Except to the extent required by law, Pfizer assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments.
This release contains forward-looking information about an agreement by Pfizer to acquire Coley Pharmaceutical Group and about Coley’s drug candidates, vaccine technology and the potential benefits of such drug candidates and technology. Such information involves substantial risks and uncertainties including, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development activities; decisions by regulatory authorities regarding whether and when to approve any drug applications for such drug candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such drug candidates; and competitive developments.
A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and in its reports on Form 10-Q and Form 8-K.
Important Additional Information: The tender offer described herein has not commenced. The description contained herein is neither an offer to purchase nor a solicitation of an offer to sell shares of Coley. At the time the tender offer is commenced, Corvette Acquisition Corp. and Pfizer intend to file a Tender Offer Statement on Schedule TO containing an offer to purchase, forms of letters of transmittal and other documents relating to the tender offer and Coley intends to file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. Pfizer and Coley intend to mail these documents to the stockholders of Coley. These documents will contain important information about the tender offer and stockholders of Coley are urged to read them carefully when they become available. Stockholders of Coley will be able to obtain a free copy of these documents (when they become available) at www.pfizer.com and www.coleypharma.com and the website maintained by the Securities and Exchange Commission at http://www.sec.gov/.
Contacts
Pfizer Inc
Shreya Prudlo (media)
212-733-4889
shreya.prudlo@pfizer.com
or
Jennifer Davis (investors)
212-733-0717
Jennifer.m.davis@pfizer.com
or
Coley Pharmaceutical Group, Inc.
Susan Hager (investors)
781-431-9019
shager@coleypharma.com
or
Karen Bergman (media)
650-575-1509
kbergman@@bccpartners.com
Print this Release
Vielleicht erfahren wir am 30.11.2007 schon mehr.
Die erste Übernahme wurde gestern bekanntgeben:
Pfizer to Acquire Coley Pharmaceutical Group
Acquisition Will Expand Pfizer’s Investment in Vaccines, Broaden Scope of Research in a Number of Key Therapeutic Areas
NEW YORK & WELLESLEY, Mass.--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today it has entered into an agreement to acquire Coley Pharmaceutical Group, Inc. (NASDAQ: COLY), a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, allergy and asthma disorders, and autoimmune diseases.
Under the terms of the agreement, Pfizer will make a cash tender offer for all of the outstanding common stock of Coley for $8.00 per share, representing an enterprise value of $164 million. The transaction is subject to customary closing conditions, including approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the acquisition by Pfizer of a majority of Coley's shares. Shareholders holding approximately 27% of the Coley shares have entered into agreements to tender their shares in the offer.
“This acquisition is an important component of Pfizer’s vaccine strategy and reflects our commitment to research new and more effective vaccines to prevent infectious diseases and to treat cancers and other debilitating conditions. Coley’s innovative product candidate portfolio and technology have the potential to significantly enhance future vaccine and immunotherapeutic approaches to a broad range of diseases including Alzheimer’s, asthma, infectious disease and oncology, where we already have strong collaborative research in place,” said Jeffrey B. Kindler, chairman and chief executive officer, Pfizer Inc.
Coley is a pioneer in a new class of drug candidates called TLR Therapeutics which work by stimulating or blocking important immune system receptors, called Toll-like receptors (TLRs), which, in turn, direct the immune system to fight disease. Coley has discovered proprietary clinical stage drug candidates targeting TLRs 7, 8 and 9.
“As a pioneer in the field of TLR-based vaccine adjuvants and immunomodulators, Coley is delighted to enter into this agreement with Pfizer, a partner who has demonstrated that they share our vision,” stated Robert L. Bratzler, President and Chief Executive Officer, Coley Pharmaceutical Group. “We believe this transaction is a strong testament to the therapeutic potential of targeting TLR pathways and reflects Pfizer’s commitment to discovering and advancing TLR Therapeutic candidates that may be capable of directing the immune system to treat a wide range of diseases.”
The acquisition is expected to close early in 2008. Lazard Frères and Co, LLC, and Covington & Burling, LLP advised Pfizer on this transaction. JPMorgan and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. advised Coley Pharmaceutical Group.
More information on both companies and the Coley TLR Therapeutics technology can be found at www.pfizer.com and www.coleypharma.com
Conference Call: Coley management will be hosting a conference call and webcast to discuss the transaction today, Friday, November 16, 2007, at 10:00am Eastern Time.
To access the live audio broadcast or the subsequent archived recording of the call, please visit the Investor Center section of the Coley website at www.coleypharma.com. Please log onto Coley’s website several minutes prior to the start of the call to ensure adequate time for any software download that may be required. A replay of this webcast will be available through November 30, 2007.
Investors may participate in the conference call by dialing either +1- 866-314-5232 in the U.S. or +1-617-213-8052 outside the U.S. and typing in the passcode 97926444. A replay of this call will be available at +1-888-286-8010 (U.S.) or +1-617-801-6888 (international) using the passcode 91373615 until November 30, 2007.
The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at www.fulldisclosure.com and institutional investors can access the call via www.streetevents.com.
PFIZER DISCLOSURE NOTICE: The information contained in this release is as of November 16, 2007. Except to the extent required by law, Pfizer assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments.
This release contains forward-looking information about an agreement by Pfizer to acquire Coley Pharmaceutical Group and about Coley’s drug candidates, vaccine technology and the potential benefits of such drug candidates and technology. Such information involves substantial risks and uncertainties including, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development activities; decisions by regulatory authorities regarding whether and when to approve any drug applications for such drug candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such drug candidates; and competitive developments.
A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and in its reports on Form 10-Q and Form 8-K.
Important Additional Information: The tender offer described herein has not commenced. The description contained herein is neither an offer to purchase nor a solicitation of an offer to sell shares of Coley. At the time the tender offer is commenced, Corvette Acquisition Corp. and Pfizer intend to file a Tender Offer Statement on Schedule TO containing an offer to purchase, forms of letters of transmittal and other documents relating to the tender offer and Coley intends to file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. Pfizer and Coley intend to mail these documents to the stockholders of Coley. These documents will contain important information about the tender offer and stockholders of Coley are urged to read them carefully when they become available. Stockholders of Coley will be able to obtain a free copy of these documents (when they become available) at www.pfizer.com and www.coleypharma.com and the website maintained by the Securities and Exchange Commission at http://www.sec.gov/.
Contacts
Pfizer Inc
Shreya Prudlo (media)
212-733-4889
shreya.prudlo@pfizer.com
or
Jennifer Davis (investors)
212-733-0717
Jennifer.m.davis@pfizer.com
or
Coley Pharmaceutical Group, Inc.
Susan Hager (investors)
781-431-9019
shager@coleypharma.com
or
Karen Bergman (media)
650-575-1509
kbergman@@bccpartners.com
Print this Release
Trading Spotlight
attraktiver finde ich allerdings Amgen.
market cap Amgen aktuell knapp 60 Mrd. Dollar. Da müssen wir wohl nicht mehr weiter diskutieren. Nach dem Lambert-Kauf hat sichs vorerst mal bei PFE mit Grossübernahmen, zual Amgen noch mal ne Kante größer ist.
Die pipeline von Amgen ist nicht schlecht, ähnlich aktuell die Situation wie bei PFE, grundsätzlich ne Top-Firma.
Im übrigen habe ich mir heute eine erste Position PFE ins DEpot gelegt, da ich keine Aktie aktuell aus dem Dow Jones kenne, in der so stark alles negative eingepreist ist. Zudem ist der freie Verfall des Kurses seit einiger zeit vorbei, wober es seit 3 Jahren seitwärts geht, jetzt nahe am unteren Rand.
Pfizer hat fast 100 Medikamente in Phase III in der pipeline, die Patentausläufe sind schon alle komplett eingepreist und sogar vielleicht etwas zu stark, zumindest, was Lipitor angeht.
Grundsätzlich ist für mich PFE ein Langfristinvestment, das ich in den nächsten jahren nicht anrühren werde.
Gruss space
market cap Amgen aktuell knapp 60 Mrd. Dollar. Da müssen wir wohl nicht mehr weiter diskutieren. Nach dem Lambert-Kauf hat sichs vorerst mal bei PFE mit Grossübernahmen, zual Amgen noch mal ne Kante größer ist.
Die pipeline von Amgen ist nicht schlecht, ähnlich aktuell die Situation wie bei PFE, grundsätzlich ne Top-Firma.
Im übrigen habe ich mir heute eine erste Position PFE ins DEpot gelegt, da ich keine Aktie aktuell aus dem Dow Jones kenne, in der so stark alles negative eingepreist ist. Zudem ist der freie Verfall des Kurses seit einiger zeit vorbei, wober es seit 3 Jahren seitwärts geht, jetzt nahe am unteren Rand.
Pfizer hat fast 100 Medikamente in Phase III in der pipeline, die Patentausläufe sind schon alle komplett eingepreist und sogar vielleicht etwas zu stark, zumindest, was Lipitor angeht.
Grundsätzlich ist für mich PFE ein Langfristinvestment, das ich in den nächsten jahren nicht anrühren werde.
Gruss space
Antwort auf Beitrag Nr.: 32.450.775 von Rambus2007 am 16.11.07 13:00:03weil zwei Kranke einen Gesunden ergeben oder warum???
Antwort auf Beitrag Nr.: 32.446.191 von Turbo23 am 15.11.07 23:56:01Jetzt fehlt nur noch die Bekanntgabe der anstehenden Übernahme:
Biogen steht ja zum Verkauf ; attraktiver finde ich allerdings Amgen.
Sollte eine diese Werte sich bald im Besitz von Pfizer befinden, wird Pfizer auch wieder anders bewertet.
Biogen steht ja zum Verkauf ; attraktiver finde ich allerdings Amgen.
Sollte eine diese Werte sich bald im Besitz von Pfizer befinden, wird Pfizer auch wieder anders bewertet.
Antwort auf Beitrag Nr.: 32.418.683 von heob am 14.11.07 08:54:45Pfizer gibt Exubera-Rechte an Nektar zurück u zahlt 135 Mio USD
http://www.finanznachrichten.de/nachrichten-2007-11/artikel-…
Pfizer Inc.: strong buy (Raymond James Financial, Inc. )
http://www.finanznachrichten.de/nachrichten-2007-11/artikel-…
http://www.finanznachrichten.de/nachrichten-2007-11/artikel-…
Pfizer Inc.: strong buy (Raymond James Financial, Inc. )
http://www.finanznachrichten.de/nachrichten-2007-11/artikel-…
Antwort auf Beitrag Nr.: 32.418.651 von Frank012 am 14.11.07 08:52:13mein gott jetzt geht dieser scheiss schon wieder los
könnt ihr bitte euren privatkrieg mittels boardmail austragen
diese postings hier interessieren nämlich kein schwein um es mal etwas direkter auszudrücken
danke für euer verständnis
könnt ihr bitte euren privatkrieg mittels boardmail austragen
diese postings hier interessieren nämlich kein schwein um es mal etwas direkter auszudrücken
danke für euer verständnis
Durchsuchen
25.04.24 · wallstreetONLINE Redaktion · BASF |
24.04.24 · Aktienwelt360 · Pfizer |
11.04.24 · dpa-AFX · Johnson & Johnson |
